Companies /Healthcare
Zevra Therapeutics Inc
NASDAQ: ZVRA Biotechnology
$11.17
▲ $0.91 (+8.87%) today
Markets closed · 5:40am ET

Zevra Therapeutics (ZVRA) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
86%
EPS beat rate
+186.05%
Avg. EPS surprise
Consecutive EPS beats
ZVRA vs Market · 30-day return after each reportZVRAS&P 500
−20%0%+20%+12.1%+2.6%Q1 25−23.3%+2.5%Q2 25−5.6%+1.9%Q3 25−14.4%+0.3%Q4 25+24.2%+0.8%Q1 26+6.7%−0.3%Q2 26
−20%0%+20%Q1 25Q3 25Q1 26
ZVRA EPS Trend · estimate vs actualEstimateActual
$0.00$0.50$1.00$1.50$-0.18$-0.06Q1 25$1.38$1.21Q2 25$-0.02$-0.01Q3 25$0.05$0.19Q4 25$0.08$0.60Q1 26$0.16$0.25Q2 26$0.18$0.26Q3 26
$0.00$0.50$1.00$1.50Q1 25Q3 25Q1 26Q3 26
ZVRA Revenue Trend · estimate vs actualEstimateActual
$0$20.0M$40.0M$17.0M$20.4MQ1 25$26.6M$25.9MQ2 25$26.6M$26.1MQ3 25$28.1M$34.1MQ4 25$32.0M$36.2MQ1 26$33.9M$39.7MQ2 26$37.4M$37.8MQ3 26
$0$20.0M$40.0MQ1 25Q3 25Q1 26Q3 26

How Often Does Zevra Therapeutics Beat Earnings Estimates?

Zevra Therapeutics beat EPS estimates in 6 of its last 7 reported quarters, and has beaten 5 quarters in a row.

Includes a mix of GAAP and Adjusted data due to ZVRA changing standards over time.

ZVRA quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 GAAP Includes $5.1 million in noncash income from fair value adjustments related to warrant and CVR liability (vs. $(5.5) million noncash expense in Q3 2025) $0.26 est. $0.18 +47.14% $37.8M est. $37.4M +0.91%
Q2 2026 Adjusted GAAP EPS of $0.14 includes $6.4 million in noncash fair value adjustments related to warrant liabilities and contingent value rights (CVR). Adjusted EPS of $0.25 excludes these items. $0.25 est. $0.16 +212.50% $39.7M est. $33.9M +17.06%
Q1 2026 $0.60 est. $0.08 +615.99% $36.2M est. $32.0M +13.33%
Q4 2025 $0.19 est. $0.05 +322.22% $34.1M est. $28.1M +21.55%
Q3 2025 $-0.01 est. $-0.02 +50.00% $26.1M est. $26.6M −2.17%
Q2 2025 $1.21 est. $1.38 −12.40% $25.9M est. $26.6M −2.86%
Q1 2025 $-0.06 est. $-0.18 +66.92% $20.4M est. $17.0M +20.30%

Figures from SEC filings and company reports. Not investment advice.